OP
SMMT icon

ORG Partners’s Summit Therapeutics SMMT Stock Holding History

ORG Partners’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$699 Hold
40
– – ﹤0.01% 1592
2025
Q3 		$826 Hold
40
– – ﹤0.01% 1414
2025
Q2 		$848 Sell
40
-25
-38% -$570 ﹤0.01% 1357
2025
Q1 		$1.22K Buy
+65
New +$1.3K ﹤0.01% 1143

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCMH
Polymer Capital Management (HK) Hong Kong $1.16B AUM 135.84% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

ORG Partners's SMMT Position: Q4 2025 in Review

ORG Partners held its Summit Therapeutics (SMMT) position steady in Q4 2025 at 40 shares worth $699. The position accounts for ﹤0.01% of the portfolio, ranked #1592.

ORG Partners first reported a position in SMMT in Q1 2025 and has held it in 4 quarters since. The position peaked at $1.22K in Q1 2025. 206 funds tracked by Wall St. Rank hold SMMT as of Q4 2025.

  • ORG Partners held 40 shares of Summit Therapeutics worth $699 as of Q4 2025.
  • ORG Partners left its Summit Therapeutics share count unchanged in Q4 2025.
  • Summit Therapeutics made up ﹤0.01% of ORG Partners's portfolio in Q4 2025, its #1592 holding.
  • ORG Partners first reported a position in Summit Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • ORG Partners's Summit Therapeutics position peaked at $1.22K in Q1 2025.
  • 206 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.